$QNRX News

Quoin Pharmaceuticals Announces Private Placement Financing of Up to $50.0 Million

Quoin Pharmaceuticals Reports Positive Interim Data from Ongoing Phase 2/3 Study of QRX003 in Netherton Syndrome

Quoin Pharmaceuticals Stock Surges Friday: What's Happening?

QNRX: Believe Conditional FDA Approval of Proposed Brand Name Reflects QRX003 Nearing Potential Commercialization

Quoin Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2026 Financial Results

Quoin Pharmaceuticals Q2 EPS $(1.90) Misses $(1.61) Estimate

Quoin Pharmaceuticals to Announce Corporate Update and Second Quarter 2026 Financial Results on Friday, August 14, 2026

Quoin Pharmaceuticals Receives FDA IND Clearance to Initiate Phase 2 Study of QRX003 in Peeling Skin Syndrome

Quoin Pharmaceuticals Receives FDA Clearance Of Its Investigational New Drug Application For QRX003 To Treat Peeling Skin Syndrome

Quoin Pharmaceuticals Receives U.S. Notice of Allowance for Patent Covering Combination Treatment for Netherton Syndrome

Quoin Pharmaceuticals Issued Notice Of Allowance From U.S. Patent And Trademark Office Titled Combination Treatment For Netherton Syndrome

Quoin Pharmaceuticals Receives FDA Conditional Approval of QYLEKI™ as the Proposed Brand Name for QRX003 for Netherton Syndrome

Quoin Pharmaceuticals Receives FDA's Conditional Approval For QYLEKI To Treat Netherton Syndrome

Quoin Pharmaceuticals Completes Establishment of Japanese Subsidiary to Advance Commercial Readiness for QRX003

Quoin Pharmaceuticals Establishes Japanese Subsidiary To Commercialize QRX003 For The Treatment Of Netherton Syndrome Upon Approval By Authorities

Quoin Pharmaceuticals Announces Positive Clinical Update from Ongoing Pediatric Netherton Syndrome Compassionate Use Program

Quoin Pharmaceuticals Announces That Four Of Six Children In Its Ongoing Pediatric Netherton Syndrome Compassionate Use Study Were Classified As 'Improved' Or 'Significantly Improved' From Baseline Across Key Clinical Endpoints

Quoin Pharmaceuticals Announces Japan's MHLW Grants Orphan Drug Designation for QRX003 in Netherton Syndrome

Quoin Pharmaceuticals QRX003 Receives Japan's Ministry Of Health, Labour And Welfare To Treat Netherton Syndrome

Quoin Pharmaceuticals Submits IND Application for QRX003 in Peeling Skin Syndrome